Research Article

Exploring the Mechanism of Skeletal Muscle in a Tacrolimus-Induced Posttransplantation Diabetes Mellitus Model on Gene Expression Profiles

Chenlei Zheng, Cheng Wang, Tan Zhang, Ding Li, Xiao-feng Ni, Jian-Hu Lin, Linxiao Sun, and Bicheng Chen

Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, Zhejiang Provincial Top Key Discipline in Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Correspondence should be addressed to Linxiao Sun; sunlinxiao@wmu.edu.cn and Bicheng Chen; bichengchen@hotmail.com

Received 19 September 2019; Revised 4 December 2019; Accepted 24 December 2019; Published 10 January 2020

Guest Editor: Yong Xu

Copyright © 2020 Chenlei Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Posttransplantation diabetes mellitus (PTDM) is a known complication of transplantation that affects the prognosis. Tacrolimus (Tac or FK506) is a widely used immunosuppressant that has been reported to be a risk factor for PTDM and to further induce complications in heart and skeletal muscles, but the mechanism is still largely unknown. In our preliminary experiments, we found that after Tac treatment, blood glucose increased, and the weight of skeletal muscle declined. Here, we hypothesize that tacrolimus can induce PTDM and influence the atrophy of skeletal muscle.

Methods. We designed preliminary experiments to establish a tacrolimus-induced PTDM model. Gene expression profiles in quadriceps muscle from this rat model were characterized by oligonucleotide microarrays. Then, differences in gene expression profiles in muscle from PTDM rats that received tacrolimus and control subjects were analyzed by using GeneSpring GX 11.0 software (Agilent). Functional annotation and enrichment analysis of differentially expressed genes (DEGs) helped us identify clues for the side effects of tacrolimus.

Results. Our experiments found that the quadriceps in tacrolimus-induced PTDM group were smaller than those in the control group. The study identified 275 DEGs that may be responsible for insulin resistance and the progression of PTDM, including 86 upregulated genes and 199 downregulated genes. GO and KEGG functional analysis of the DEGs showed a significant correlation between PTDM and muscle development. PPI network analysis screened eight hub genes and found that they were related to troponin and tropomyosin.

Conclusions. This study explored the molecular mechanism of muscle atrophy in a tacrolimus-induced PTDM model by bioinformatics analyses. We identified 275 DEGs and identified significant biomarkers for predicting the development and progression of tacrolimus-induced PTDM.

1. Introduction

Posttransplantation diabetes mellitus (PTDM) is a known complication of transplantation [1]. It has been reported to be associated with cardiovascular disease, skeletal muscle dysfunction, graft failure, and the length of patient survival [2–5]. PTDM may also affect the long-term outcomes of transplant patients. Early detection of PTDM risk factors and PTDM management are concerns of posttransplantation care. Several risk factors for PTDM have been reported, including age, body mass index, hepatitis C infection [6–10], and immunosuppressive medication [7, 11].

Tacrolimus (Tac or FK506) has been reported as a risk factor for PTDM because it can cause insulin hyposecretion [5, 7, 12]. A previous study reported that during the first 5-month Tac treatment period, rats suffer from decreased insulin secretion, inducing increase insulin resistance, and undergo islet cell injury [13]. Impaired energy metabolism in skeletal muscle occurs with the development of diabetes mellitus [14]. It has been reported that DM induces muscle...
atrophy and transformed fiber type from oxidative to glycolytic [15–17]. However, the mechanism remains largely unknown.

Gene expression profiles measure the expression of thousands of genes simultaneously to build a global picture of cell function, and gene expression profiling can be used as an important diagnostic test [18, 19]. This technique may have positive influence to improve our knowledge of transplantation and facilitate the screening and early detection of complications.

Therefore, we hypothesize that tacrolimus induces PTDM and affects skeletal muscle function such as atrophy. It has been reported that quadriceps are kinds of oxidative muscle which were closely related to insulin resistance [20] while the muscle fiber types of gastrocnemius are glycolytic type [20]. Our preliminary study had shown peroxisome proliferator-activated receptor- γ (PPAR-γ) which was related to insulin resistance in Tac-induced PTDM expressed in quadriceps [21]. So, quadriceps and gastrocnemius were dissected from the PTMD model induced by Tac to test this hypothesis. In this work, we characterized gene expression profiles of muscle from a rat model using oligonucleotide microarrays. DEGs between tacrolimus-induced PTDM model tissues and normal tissue samples were identified through gene expression profiling. In the end, several candidate genes were identified to be responsible for the progression of PTDM and effects on skeletal muscle. Our results offer information on this PTDM model and provide potential therapeutic targets for further studies.

2. Materials and Methods

2.1. Material. Tacrolimus capsules, approval number: Zhunzi 20090142, were purchased from Astellas Pharma Co., Ltd. (China); saline was purchased from Haili Chen Biotechnology Co., Ltd.; chloral hydrate was purchased from Shanghai to Beijing Biological Technology Co., Ltd. Cable; a blood glucose meter and blood glucose test strips were purchased from Changsha Sannuo Biosensing Co.; and TRIzol reagent was purchased from Gibco BRL.

2.2. Preliminary Study. We designed preliminary experiments to establish the maximum dose of tacrolimus needed to control clinical conditions of most of the patients to determine the target trough plasma levels of tacrolimus (≤20 ng/mL). We treated three groups of animals with i.p. tacrolimus (0.1, 1, and 10 mg/kg/day). Animals were treated for 7 days, and plasma levels of the drug were serially measured. The target trough level of tacrolimus was achieved with a dose of 1 mg/kg/day.

2.3. Animal Treatment to Establish the PTDM Rat Model. Male Sprague-Dawley rats (body weight: 200-250 g) were obtained from Vital River Laboratory Animal Technology Co. Ltd., housed in cages at 22°C under a 12 h light-dark cycle, and fed commercial pellet chow ad libitum. All animal care, use, and experimental protocols were submitted and approved by The Tab of Animal Experimental Ethical Inspection of Laboratory Animal Centre, Wenzhou Medical University. Groups of rats were injected once a day with saline (control) or FK506 in saline (1 mg/kg BW). Body weight and glucose, which was measured in the tail blood with an Accu-check Sensor instrument, were regularly recorded every two days at the end of the light period. Once the treatment finished, animals were euthanized and their quadriceps and gastrocnemius were dissected out.

2.4. Histopathological Analysis. The quadriceps and gastrocnemius of both groups were collected and weighed and then fixed in paraformaldehyde for 36 h. The tissues were dehydrated in graded ethanol solutions, vitrified with dimethylbenzene, and embedded in paraffin. Paraffin-embedded muscles were cut into 4.5 μm sections and then deparaffinized and rehydrated. The muscles were stained with hematoxylin-eosin (HE; Solarbio) and observed with a light microscope at 200x. The cross-section area was determined for at least 100 fibers per tissue.

2.5. RNA Isolation and Microarray Analysis. This dataset included 6 samples of quadriceps muscle from PTDM rats that received tacrolimus and normal rats with three biological replicates. RNA was extracted from the samples with TRIzol reagent according to the manufacturer’s protocol. RNA was reverse transcribed by a RevertAid First Strand cDNA Synthesis Kit. Further labeling and microarray hybridization experiments and washes were performed at GeneChem (Shanghai, China). Microarray analysis was performed on an Agilent platform (Agilent Technologies, USA). Differentially expressed genes in PTDM rats were defined as follows: (1) normalized intensity: after normalizing with median scaling normalization method, take the average of repeated data from the same sample. The software of Rosetta Resolver was used to list normalized data (2) p value < 0.05 and minimum fold change > 1.5 (absolute value of log2 ratios is ≥0.585) using GeneSpring GX 11.0 software (Agilent) and (3) a difference of intensity between the two groups ≥ 1000 when the log2 ratios = NA.

2.6. Functional Analysis of DEGs. GO and KEGG enrichment analysis of differentially expressed genes in skeletal muscle from PTDM rats was performed using WebGestalt. Web Gene Ontology Annotation Plot (WEGO 2.0) was used to visualize the GO classification results. The STRING database (http://string-db.org) is a system for determining interactions between genes or proteins and was used to guide the construction of the PPI network of downregulated top 50 DEGs to explore functional interactions [22]. Parameters used to retrieve the information from STRING were default. Only nodes with combined score > 0.900 and node degree ≥ 1 were included in the PPI networks. Experiments and databases were chosen as active interaction sources.

2.7. Quantitative Real-Time PCR (qRT-PCR). The RNA expression of Tpm3, Tnnc1, Tnn1, Tnni3, Hrh3, Apln, S1pr3, and Cxcl12 was detected by qRT-PCR. The experiment was performed with FastStart Universal SYBR Green Master (ROX) using a machine of 7500 Fast machine (Applied Biosystems). GAPDH was used as an internal
Table 1: Sequences of the primers used for quantitative real-time PCR.

| Gene  | Forward primer (5′–3′)           | Reverse primer (5′–3′)     |
|-------|----------------------------------|---------------------------|
| GAPDH | GACATGGCGGCTGGAGAAAC             | AGCCCCAGGATGCCCTTTAGT     |
| Tpm3  | CAGTCTCCAGTGGTCACAGGTG           | TCAGCTCGGTCAGGACATTCTC    |
| Tnn1  | AGGCTGATGGTCACATTGAG            | TCGTGTCTGTGTCACCGTCCTC    |
| Tnn1  | CAGGCAGAAGATGAGGAAGCAGTG         | CGGAGGAATCAAAGGAGGAACCAC  |
| Tnnt1 | ACGCTCGTGTGGACAAATGG            | ACTTGCCAGGCGGTACATAG      |
| Tnni3 | CAGGCAGAAGATGAGGAAGCAGT         | CAATTGCGAAGGAGCAGCAC      |
| Hrh3  | TCTGTTCTATGGCGCATTTCAC          | GGGCTCTGACTTTCTGTGGTTG    |
| Apln  | GGTTGGTGTCGCCGTGCTCTG           | AGAGTGCTGCTGCTGTTTAC      |
| S1pr3 | TATCTCGGCGGCTCACCAG            | AAACCATCGCTCGTAGACACTG    |
| Cxcl12|                                |                           |

Figure 1: Skeletal muscle atrophy in rats with posttransplantation diabetes mellitus (PTDM). Blood glucose concentrations before and after the injection (a, b). Body weight of the rats (c). Wet weight of quadriceps and gastrocnemius (d). Cross-section area of quadriceps and gastrocnemius stained with hematoxylin and eosin (e). The data of cross-section area (f). Scale bars represent 50 μm. Data are means ± SD. *p < 0.05, **p < 0.01, ****p < 0.0001.
Table 2: Quality control result.

| Item | Background average intensity Mean of background intensity (Cy5) < 200 | Internal control gene Mean of IHC intensity > 37500 | Hybridization control ETQC high | ETQC median | ETQC low |
|------|-----------------------------------------------------|-------------------------------------------------|--------------------------------|-------------|----------|
| Control 1 | 110 | 55446 | 309703 | 71525 | 5099 |
| Control 2 | 106 | 62694 | 295396 | 70600 | 5255 |
| Control 3 | 95 | 77902 | 373575 | 74693 | 5801 |
| Tac 1 | 101 | 48665 | 319491 | 73558 | 5223 |
| Tac 2 | 98 | 46770 | 340991 | 74995 | 5517 |
| Tac 3 | 101 | 61230 | 338713 | 72997 | 5549 |

Figure 2: Differentially expressed genes profiles. Heat map of DEGs in Tac rats and controls (a). Principal component analysis (PCA) of DEGs (b).
Figure 3: GO classification analysis of upregulated (a) and downregulated (b) DEGs.
standard, and the results were analyzed by the ΔΔCt method. The sequences of the primers used are listed in Table 1.

2.8. Statistical Analyses. All data are presented as mean values ± SD and performed using one-way ANOVA. p values < 0.05 were considered statistically significant.

3. Results

3.1. Establishment of a Rat Model of PTDM. The PTDM rats were treated as described. The blood glucose concentrations of the PTDM and control groups were 4.48 ± 0.92 and 4.49 ± 0.73 mmol/L, respectively (p > 0.05), before the injection. After two weeks of treatment, the blood glucose concentrations of the two groups were 19.51 ± 4.22 and 6.87 ± 2.05 mmol/L, respectively, and the concentration of the PTDM group was significantly higher than that of the control group (p < 0.01) (Figures 1(a) and 1(b)). The body weight of the rats increased in both groups during the study, and the control group weighted more heavier than the Tac group (p < 0.0001) (Figure 1(c)). The wet weight of quadriceps in the Tac group was lighter than that in the control group (p < 0.0001) (Figure 1(d)). The cross-section area of pathological section in quadriceps showed that the Tac group was smaller than the control group (p < 0.05). Those gaps between muscle fibers were narrow in the control group. Fibers of quadriceps obtained from Tac rats exhibited atrophy and disordered arrangement (Figures 1(e) and 1(f)). The weight and cross-section area of gastrocnemius in the control and Tac groups were not significantly different (Figures 1(d)–1(f)).

3.2. Differential mRNA Expression in Muscle from PTDM Rats. The quality of the samples is shown in Table 2. Background intensity in the channel (Cy5) of the two groups is <200. About the internal control gene, mean of IHC intensity is >37500. ETQC, labeled-spike-in hybridization controls

![Table 3: Functional enrichment analysis of downregulated expression DEGs.](https://example.com/table3)

| Term ID        | Term                                           | Gene no. | FDR     |
|----------------|------------------------------------------------|----------|---------|
| GO:0050879     | Multicellular organismal movement              | 6        | 0.003027|
| GO:0061061     | Muscle structure development                    | 16       | 0.004976|
| GO:0003013     | Circulatory system process                      | 14       | 0.006516|
| GO:0043292     | Contractile fiber                               | 13       | 1.31E-05|
| GO:0003779     | Actin binding                                   | 13       | 0.002935|
| GO:0050839     | Cell adhesion molecule binding                  | 8        | 0.037984|
| rno04260       | Cardiac muscle contraction                      | 7        | 0.001767|
| rno05410       | Hypertrophic cardiomyopathy (HCM)               | 7        | 0.001767|
| rno05414       | Dilated cardiomyopathy (DCM)                    | 7        | 0.001767|

Figure 4: KEGG classification analysis of upregulated and downregulated DEGs. (a) Cellular processes. (b) Environmental information processing. (c) Genetic information processing. (d) Metabolism. (e) Organismal systems.
Cardiac muscle contraction

Depolarization

Cardiac myocyte

Calcium signaling pathway

Sarcoplasmic reticulum (SR)

DHRP

JCN

RyR2

TRDN HRC HRC

NCX ATP NHE

CASQ2

SERCA2a

TnC

Uniporter Cyto

NHX

PM

Actin

Myosin

Myofilaments

Systole

Diastole

Ca2+

2Na+

H+

3Na+   H+

Mitochondria

3Na+ 2K+

Myofilament is activated by calcium and bind to troponin C. Troponin combines with tropomyosin and actin through the inhibitory protein troponin I without calcium.

Figure 5: KEGG pathway of cardiac muscle contraction (a) and PI3K-Akt signaling pathway (b).
with low, median, and high concentrations, represents a concentration-dependent intensity gradient. The range of ETQC median of six simples was between 70600 and 74995. The quality control results show that all of the samples pass the inspection standard. Heat map analysis (Figure 2(a)) demonstrated differences in mRNA expression levels between the PTDM and control groups considering a p value cutoff of 0.05 and a fold change cutoff of 1.5 (upregulated or downregulated). According to the threshold in this study, we identified 275 differentially expressed genes, 86 upregulated genes and 199 downregulated genes, between these two groups. The majority of differentially expressed genes in muscle from PTDM rats exhibited expression levels with a fold change lower than 4.0 (up or down) when compared to those in muscle from control subjects, and a few genes showed a fold change ≥ 4.0. The principal component analysis (PCA) (Figure 2(b)) score plot of DEGs showed a clear separation between the control and Tac groups, suggesting that Tac has a firm effect on the muscle of rats.

3.3. GO Enrichment Analysis of DEGs. To assess the function of the differentially expressed genes in skeletal muscle, we first assigned the genes to different GO levels. The GO classification analysis showed a relatively high abundance of genes involved in binding and cellular processes (Figure 3). Then, we performed enrichment analysis of the cell component, biological process, and molecular function categories and KEGG pathway analysis through WebGestalt with the rat genome as a reference. For the upregulated genes, no significant enrichment items with FDR < 0.05 were found. When we focused on downregulated genes, several significant enrichment items with FDR < 0.05 showed interesting phenomena regarding skeletal muscle (Table 3).

According to GO enrichment analysis, downregulated differentially expressed genes between control and PTDM rats were significantly enriched in multicellular organismal movement, muscle structure development, and circulatory system processes in the biological process category, contractile fibers in the cell component category, and actin binding and cell adhesion molecule binding in the molecular function category. These findings indicated that the GO categories of these differentially expressed probes were predominantly related to muscle function and movement.

3.4. KEGG Pathway Analysis of DEGs. The KEGG classification analysis of upregulated and downregulated DEGs was shown in Figure 4. Clearly, the environmental information processing especially signal transduction was significantly higher than other pathways. The classification of translation and replication and repair was related to upregulated DEGs only, while sensory system, excretory system, metabolism of terpenoids and polyketides, glycan biosynthesis and metabolism, biosynthesis of other secondary metabolites, and cell motility were shown in downregulated DEGs. Clearly, the proportion of genes related to signal transduction was significantly higher than that of genes related to other pathways. Interestingly, the cardiac muscle contraction pathway (Figure 5(a)) and calcium signaling pathway (a subset of the signal transduction pathway) had the largest and second largest number of downregulated DEGs, respectively, which indicated that there was a relationship between muscle and PTDM in rats.

Functional enrichment KEGG analysis of downregulated DEGs, as shown in Table 3, showed that the cardiovascular system pathway was significantly differentially expressed between control and PTDM rats. The results showed that the downregulated DEGs participate in muscle contraction and relaxation.

The upregulated DEGs PP2A and ECM as well as downregulated DEGs such as GF, cytokine R, ITGA, and p21 were shown to be involved in the PI3K-Akt signaling pathway (Figure 5(b)). Akt has been reported to be responsible for glucose uptake in skeletal muscle [23].

3.5. PPI Network of the DEGs and Hub Genes. As seen from the above analysis results, significant functional enrichment was found only in downregulated genes. We further explored whether there was a close significant relationship between the downregulated genes. The PPI network of 41 candidate rat genes obtained by screening for downregulated genes that were significantly enriched in GO and KEGG functions is shown in Figure 6.

A PPI enrichment p value < 1.0e-16 means that those proteins have more interactions among themselves than what would be expected for a random set of proteins of similar size, drawn from the rat genome. Such an enrichment indicates that the proteins are at least partially biologically connected, as a group. There were 24 nodes and 31 edges in the PPI network based on the top 50 DEGs between two groups, and the average node degree was 2.58. The PPI network contained 8 hub genes according to our criterion, which were Tpm3, Tnn1, Tnn1, Tnn1, Hrh3, Apln, S1pr3, and Cxcl12, and all of these genes are related to tropinin, myosin, and muscle (Table 4). All of the core genes in the Tac group were validated through the low expression by qPCR (Figure 7).

4. Discussion

With the rapid development of the Chinese economy, the number and quality of transplant surgeries have improved dramatically. Immunosuppressive agents such as tacrolimus are necessary for patients to improve the survival of grafts after kidney transplantation. Unfortunately, long-term use of tacrolimus can lead to serious complications, such as post-transplantation diabetes mellitus (PTDM) which is one of the most severe complications of transplantation and influences
The conformational change of troponin inhibits the binding of troponin I and actin, which results in systole [32].

Cardiac muscle contraction is also regulated by troponin and tropomyosin. Troponin is made up of troponin C, troponin I, and troponin T. Under low calcium conditions, troponin combines with tropomyosin and actin through the inhibitory protein troponin I, which leads to the diastole of the myocardium. On the other hand, the activation of myofilament and binding to troponin C are attributed to calcium. The conformational change of troponin inhibits the binding of troponin I and actin, which results in systole [32].

In this study, the microarray method was used to investigate gene expression profiles in Tac-induced PTDM and control subjects. A list of 275 differentially expressed genes (86 upregulated and 199 downregulated) was identified in Tac-treated rats. GO classification analysis showed downregulated expression of DEGs related to muscle structure development. The DEGs were also associated with contractile fibers as a cellular component, actin binding as a molecular function, and so on.

We further built a PPI network of 50 top DEGs, which is shown in Figure 6, and finally identified 8 hub genes: Tpm3, Tnnc1, Tnnt1, Tnni3, Hrh3, Apln, S1pr3, and Cxcl12. Tpm3 (Tropomyosin alpha-3 chain) is an actin-associated protein involved in stress fiber formation [26, 23]. Tropomyosin consists of four genes, including Tpm1, 2, 3, and 4, all of which have different and important functions [33]. Tpm3 promotes the breakdown of glucose and the synthesis of glycogen [23]. The Tnnc1 (Troponin C type 1) gene is a sarcomeric calcium sensor expressed in both slow skeletal and cardiac tissues. Tnnt1 (Troponin T1) is a kind of slow skeletal muscle troponin T (ssTnT) [34]. It is reported that ssTnT deficiency resulted in smaller type I fiber [34]. The incapacity of ssTnT to form troponin complex or bind tropomyosin may be the reason for its sensitivity to degradation [35]. It has been reported that the Tnni3 (Troponin I, cardiac muscle) protein changes the activity of actomyosin ATPase, which is involved in the sensing of calcium [36]. Hrh3 (Histamine Receptor H3) was reported to modulate cardiac sympathetic activity and hence ameliorate myocardial remodeling [37]. Apln (Apelin) as a myokine has been used to improve metabolic effects by reducing obesity-related insulin resistance [38–40]. Apelin is associated to mitochondrial function by stimulating Akt through its Gi alpha subunit-coupled receptor APLNR in skeletal muscle cells [41]. S1pr3 (Sphingosine-1-Phosphate Receptor 3) is a target of miR-127, which can enhance myogenic cell differentiation [42]. Cxcl12 (C-X-C Motif Chemokine Ligand 12) promotes the development of myogenesis and regeneration of muscle [43]. Cxcl12 plays an important part in maintaining muscle function ability and homeostasis [44]. The results of this research may help explain the induction of tacrolimus-induced postransplantation diabetes mellitus via the low expression of muscle genes including Tpm3, Tnnc1, Tnnt1, Tnni3, Hrh3, Apln, S1pr3, and Cxcl12. In the end, these hub genes may serve as new targets for PTDM and provide direction or for clinical treatment.

### Table 4: Functional annotation of hub genes.

| Gene ID | Gene name                          | Description                                                                 |
|---------|------------------------------------|-----------------------------------------------------------------------------|
| Tpm3    | Tropomyosin alpha-3 chain          | Binds to actin filaments in muscle and nonmuscle cells                     |
| Tnnc1   | Troponin C type 1                  | Slow skeletal and cardiac muscles                                           |
| Tnnt1   | Troponin T1                        | The tropomyosin-binding subunit of troponin                                |
| Tnni3   | Troponin I, cardiac muscle         | The inhibitory subunit of troponin                                         |
| Hrh3    | Histamine Receptor H3              | Increase voltage-dependent calcium current in smooth muscles                |
| Apln    | Apelin                             | Activate specific signaling pathways that regulate insulin secretion        |
| S1pr3   | Sphingosine-1-Phosphate Receptor 3 | A G-protein-coupled receptor for the bioactive sphingosine-1-phosphate, which is an important regulator of skeletal muscle function |
| Cxcl12  | C-X-C Motif Chemokine Ligand 12   | Plays a protective role after myocardial infarction                         |

In this study, the microarray method was used to investigate gene expression profiles in Tac-induced PTDM and control subjects. A list of 275 differentially expressed genes (86 upregulated and 199 downregulated) was identified in Tac-treated rats. GO classification analysis showed downregulated expression of DEGs related to muscle structure development. The DEGs were also associated with contractile fibers as a cellular component, actin binding as a molecular function, and so on.

We further built a PPI network of 50 top DEGs, which is shown in Figure 6, and finally identified 8 hub genes: Tpm3, Tnnc1, Tnnt1, Tnni3, Hrh3, Apln, S1pr3, and Cxcl12. Tpm3 (Tropomyosin alpha-3 chain) is an actin-associated protein involved in stress fiber formation [26, 23]. Tropomyosin consists of four genes, including Tpm1, 2, 3, and 4, all of which have different and important functions [33]. Tpm3 promotes the breakdown of glucose and the synthesis of glycogen [23]. The Tnnc1 (Troponin C type 1) gene is a sarcomeric calcium sensor expressed in both slow skeletal and cardiac tissues. Tnnt1 (Troponin T1) is a kind of slow skeletal muscle troponin T (ssTnT) [34]. It is reported that ssTnT deficiency resulted in smaller type I fiber [34]. The incapacity of ssTnT to form troponin complex or bind tropomyosin may be the reason for its sensitivity to degradation [35]. It has been reported that the Tnni3 (Troponin I, cardiac muscle) protein changes the activity of actomyosin ATPase, which is involved in the sensing of calcium [36]. Hrh3 (Histamine Receptor H3) was reported to modulate cardiac sympathetic activity and hence ameliorate myocardial remodeling [37]. Apln (Apelin) as a myokine has been used to improve metabolic effects by reducing obesity-related insulin resistance [38–40]. Apelin is associated to mitochondrial function by stimulating Akt through its Gi alpha subunit-coupled receptor APLNR in skeletal muscle cells [41]. S1pr3 (Sphingosine-1-Phosphate Receptor 3) is a target of miR-127, which can enhance myogenic cell differentiation [42]. Cxcl12 (C-X-C Motif Chemokine Ligand 12) promotes the development of myogenesis and regeneration of muscle [43]. Cxcl12 plays an important part in maintaining muscle function ability and homeostasis [44]. The results of this research may help explain the induction of tacrolimus-induced postransplantation diabetes mellitus via the low expression of muscle genes including Tpm3, Tnnc1, Tnnt1, Tnni3, Hrh3, Apln, S1pr3, and Cxcl12. In the end, these hub genes may serve as new targets for PTDM and provide direction or for clinical treatment.
5. Conclusion

Tacrolimus-induced PTDM is a severe complication of post-transplantation with poor prognosis. This study attempted to identify the association between tacrolimus and PTDM by using bioinformatics analysis. Functional analysis of 275 DEGs between the tacrolimus-induced PTDM group and the control group illustrated that muscle atrophy of PTDM is induced by tacrolimus through inhibition of the expression of Tpm3, TnnC1, TnnT1, TnnT3, Hrh3, Apn, S1pr3, and Cxcl12. The target genes we found may have a guiding significance for predicting or even reducing the risk to patients. Moreover, the next study will focus on experiments such as western blotting and PCR in clinical cases.

Data Availability

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Chenlei Zheng and Cheng Wang contributed equally to this work.

Acknowledgments

This work was supported by Project of Wenzhou Science & Technology Bureau (No. Y20140672).

Supplementary Materials

Supplementary 1. Supplement 1 is the differentially expressed genes including 86 upregulated and 199 downregulated genes of control and PTDM rats with Tacrolimus groups.

Supplementary 2. Supplement 2 is the detail attributes of PPI network.

References

[1] T. Jouve, J. Noble, L. Rostaing, and P. Malvezzi, “An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization,” Expert Opinion on Drug Safety, vol. 18, no. 4, pp. 285–294, 2019.

[2] B. Einollahi, M. Jalalzadeh, S. Taheri, M. Nafar, and N. Simforoosh, “Outcome of kidney transplantation in type 1 and type 2 diabetic patients and recipients with posttransplant diabetes mellitus,” Urology Journal, vol. 5, no. 4, pp. 248–254, 2008.

[3] E. Sulanc, J. T. Lane, S. E. Puumala, G. C. Groggel, L. E. Wennshall, and R. B. Stevens, “New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines,” Transplantation, vol. 80, no. 7, pp. 945–952, 2005.

[4] T. G. Valderhaug, J. Hjelmesaeth, T. Jønsen, J. Raalslien, T. Levestad, and A. Hartmann, “Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses,” Transplantation Journal, vol. 94, no. 7, pp. 714–720, 2012.

[5] C. J. Yates, S. Fourlanos, J. Hjelmesaeth, P. G. Colman, and S. J. Cohnen, “New-onset diabetes after kidney transplantation—changes and challenges,” American Journal of Transplantation, vol. 12, no. 4, pp. 820–828, 2012.

[6] H. W. Chan, C. Y. Cheung, Y. L. Liu et al., “Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients: a single centre study,” Nephrology Dialysis Transplantation, vol. 23, no. 10, pp. 3337–3342, 2008.

[7] T. Shah, A. Kasravi, E. Huang et al., “Risk factors for development of new-onset diabetes mellitus after kidney transplantation,” Transplantation, vol. 82, no. 12, pp. 1673–1676, 2006.

[8] Y. M. Bee, H. C. Tan, T. L. Tay, T. Y. Kee, S. Y. Goh, and P. C. Kek, “Incidence and risk factors for development of new-onset diabetes after kidney transplantation,” Annals of the Academy of Medicine, Singapore, vol. 40, pp. 160–167, 2011.

[9] N. Kamar, C. Mariat, M. Delahousse et al., “Diabetes mellitus after kidney transplantation: a French multicentre observational study,” Nephrology Dialysis Transplantation, vol. 22, no. 7, pp. 1986–1993, 2007.

[10] J. M. Morales, R. Bloom, and D. Roth, “Kidney transplantation in the patient with hepatitis C virus infection,” in Hepatitis C in Renal Disease, Hemodialysis and Transplantation, vol. 176, pp. 77–86, Karger, Basel, 2012.

[11] B. Borda, E. Szederkényi, C. Lengyel et al., “Functional and Histopathologic Changes in Renal Transplant Patients With New-Onset Diabetes and Dyslipidemia,” Transplantation Proceedings, vol. 43, no. 4, pp. 1254–1258, 2011.

[12] L. Santos, E. Rodrigo, C. Piñera et al., “New-onset diabetes after transplantation: drug-related risk factors,” Transplantation Proceedings, vol. 44, no. 9, pp. 2585–2587, 2012.

[13] C. Xu, Y.-J. Niu, X.-J. Liu et al., “Tacrolimus reversibly reduces insulin secretion, induces insulin resistance, and causes islet cell damage in rats,” International Journal Of Clinical Pharmacology and Therapeutics, vol. 52, no. 7, pp. 620–627, 2014.

[14] S. Fujimaki and T. Kuwabara, "Diabetes-induced dysfunction of mitochondria and stem cells in skeletal muscle and the nervous system," International Journal of Molecular Sciences, vol. 18, no. 10, p. 2147, 2017.

[15] W. L. Sexton, D. C. Poole, and O. Mathieu-Costello, "Microvascularity structure-function relationships in skeletal muscle of diabetic rats," American Journal of Physiology-Heart and Circulatory Physiology, vol. 266, no. 4, pp. H1502–H1511, 1994.

[16] H. Andersen, P. C. Gadeberg, B. Brock, and J. Jakobsen, “Muscular atrophy in diabetic neuropathy: a stereological magnetic resonance imaging study,” Diabetologia, vol. 40, no. 9, pp. 1062–1069, 1997.

[17] A. Oberbach, Y. Bossenz, S. Lehmann et al., “Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes,” Diabetes Care, vol. 29, no. 4, pp. 895–900, 2006.

[18] A. N. Y. Cheung, "Molecular targets in gynaecological cancers," Pathology, vol. 39, no. 1, pp. 26–45, 2007.

[19] Z. Magic, S. Radulovic, and M. Brankovic-Magic, "cDNA microarrays: identification of gene signatures and their application in clinical practice," Journal of B.U.ON, vol. 12, Supplement 1, pp. S39–S44, 2007.
N. M. Rizk, D. A. Meier, D. J. Pastorek, G. R. Krakower, and A. H. Kissebah, "Glucose Utilization in Muscle Fiber Types: Use of the Partial Pancreatectomized Rat Model to Distinguish Effects of Glucose and Insulin on Insulin Resistance," *Molecular Genetics And Metabolism*, vol. 65, no. 1, pp. 44–50, 1998.

L. Zhang, Y. He, C. Wu et al., "Altered expression of glucose metabolism associated genes in a tacrolimus-induced post-transplantation diabetes mellitus in rat model," *International Journal of Molecular Medicine*, vol. 44, no. 4, pp. 1495–1504, 2019.

S. Jayashree, P. Murugavel, R. Sowdhaminii, and N. Srinivasan, "Interface residues of transient protein-protein complexes have extensive intra-protein interactions apart from inter-protein interactions," *Biology Direct*, vol. 14, no. 1, p. 1, 2019.

A. J. Kee, L. Yang, C. A. Lucas et al., "An actin filament population defined by the tropomyosin Tpm3.1 regulates glucose uptake," *Traffic*, vol. 16, no. 7, pp. 691–711, 2015.

F. G. Cosio, T. E. Pesavento, K. Osei, M. L. Henry, and R. M. Ferguson, "Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years," *Kidney International*, vol. 59, no. 2, pp. 732–737, 2001.

F. G. Cosio, Y. Kudva, M. van der Velde et al., "New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation," *Kidney International*, vol. 67, no. 6, pp. 2415–2421, 2005.

A. V. Edhager, J. A. Povlsen, B. Lofgren, H. E. Botker, and J. Palmfeldt, "Proteomics of the rat myocardium during development of type 2 diabetes mellitus reveals progressive alterations in major metabolic pathways," *Journal of Proteome Research*, vol. 17, no. 7, pp. 2521–2532, 2018.

R. Gimenes, C. Gimenes, C. M. Rosa et al., "Influence of apocynin on cardiac remodeling in rats with streptozotocin-induced diabetes mellitus," *Cardiovascular Diabetology*, vol. 17, no. 1, p. 15, 2018.

Y. M. Cho, K. S. Park, H. S. Jung et al., "High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria," *Diabetes Care*, vol. 26, no. 4, pp. 1123–1128, 2003.

J. Zhang, D. A. Nugrahaningrum, O. Marcelina et al., "Tyrosol facilitates neovascularization by enhancing skeletal muscle cell viability and paracrine function in diabetic hindlimb ischemia mice," *Frontiers in Pharmacology*, vol. 10, p. 909, 2019.

K. Ahmad, E. Lee, J. Moon, S.-Y. Park, and I. Choi, "Multifaceted interweaving between extracellular matrix, insulin resistance, and skeletal muscle," *Cells*, vol. 7, no. 10, p. 148, 2018.

M. Uda, H. Kawasaki, K. Iizumi et al., "Sumoylated α-skeletal muscle actin in the skeletal muscle of adult rats," *Molecular and Cellular Biochemistry*, vol. 409, no. 1-2, pp. 59–66, 2015.

P. Vanburen and B. M. Palmer, "Cooperative activation of the cardiac myofilament: the pivotal role of tropomyosin," *Circulation*, vol. 121, no. 3, pp. 351–353, 2010.

S. A. Savill, H. F. Leitch, J. N. Harvey, and T. H. Thomas, "Inflammatory adipokines decrease expression of two high molecular weight isoforms of tropomyosin similar to the change in type 2 diabetic patients," *PLoS One*, vol. 11, no. 9, article e0162908, 2016.

B. Wei, Y. Lu, and J. P. Jin, "Deficiency of slow skeletal muscle troponin T causes atrophy of type I slow fibres and decreases tolerance to fatigue," *The Journal of Physiology*, vol. 592, no. 6, pp. 1367–1380, 2014.

X. Wang, Q. Q. Huang, M. T. Breckenridge et al., "Cellular fate of truncated slow skeletal muscle troponin T produced by Glu180 nonsense mutation in amish nemaline myopathy," *The Journal of Biological Chemistry*, vol. 280, no. 14, pp. 13241–13249, 2005.

Y. Zhao, Y. Feng, Y.-M. Zhang et al., "Targeted next-generation sequencing reveals hot spots and doubly heterozygous mutations in Chinese patients with familial cardiomyopathy," *BioMed Research International*, vol. 2015, Article ID 561819, 11 pages, 2015.

G.-H. He, W. K. Cai, J. B. Zhang et al., "Associations of Polymorphisms in HRH2 , HRH3 , DAO, and HNMT Genes with Risk of Chronic Heart Failure," *BioMed Research International*, vol. 2016, Article ID 1208476, 8 pages, 2016.

I. Castan-Laurell, C. Dray, C. Attané, T. Duparc, C. Knauf, and P. Valet, "Apelin, diabetes, and obesity," *Endocrine*, vol. 40, no. 1, pp. 1–9, 2011.

C. Dray, C. Debard, J. Lager et al., "Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 298, no. 6, pp. E1161–E1169, 2010.

C. Dray, C. Knauf, D. Daviaud et al., "Apelin stimulates glucose utilization in normal and obese insulin-resistant mice," *Cell Metabolism*, vol. 8, no. 5, pp. 437–445, 2008.

C. Vinel, L. Lukjanenko, A. Batut et al., "The exerkine apelin reverses age-associated sarcopenia," *Nature Medicine*, vol. 24, no. 9, pp. 1360–1371, 2018.

L. Zhai, R. Wu, W. Han, Y. Zhang, and D. Zhu, "miR-127 enhances myogenic cell differentiation by targeting S1PR3," *Cell Death & Disease*, vol. 8, no. 3, article e2707, 2017.

M. Puchert, V. Adams, A. Linke, and J. Engele, "Evidence for the involvement of the CXCL12 system in the adaptation of skeletal muscles to physical exercise," *Cellular Signalling*, vol. 28, no. 9, pp. 1205–1215, 2016.

E. Brzoska, M. Kowalewska, A. Markowska-Zagrajek et al., "Sdf-1 (CXCL12) improves skeletal muscle regeneration via the mobilisation of Cxcr4 and CD34 expressing cells," *Biology of the Cell*, vol. 104, no. 12, pp. 722–737, 2012.